Search is not available for this dataset
data stringlengths 198 8.94k | criteria stringlengths 19 16.5k | NCT_ID stringlengths 19 19 | Study_Name stringlengths 29 311 | __index_level_0__ int64 0 22.6k |
|---|---|---|---|---|
Study Objectives
Oncological home-hospitalization might be a patient-centred, cost-effective approach to deal wiht the current challenges in cancer healthcare.
The primary aim of this clinical trial is to evaluate patient-reported quality of life of patients receiving (partial) oncological home-hospitalization and to ... | Inclusion Criteria:
* Starting new oncological treatment at the outpatient hospital
* ECOG <= 2
* Living within 30 minutes of drive from the hospital
Exclusion Criteria:
* Important comorbidity (ECOG > 2)
* Life expectancy < 6 months
* Simultaneous treatment with radiotherapy
* Taking part in clinical trial with any... | NCT_ID
NCT03668275
| Study_NameEvaluating Quality and Cost of (Partial) Oncological Home-Hospitalization
| 12,560 |
Study Objectives
This randomized phase II trial studies how well cabozantinib-s-malate works compared with temozolomide or dacarbazine in treating patients with melanoma of the eye (ocular melanoma) that has spread to other parts of the body and cannot be removed by surgery. Cabozantinib-s-malate may stop the growth of... | Inclusion Criteria:
* Histologically or cytologically confirmed uveal melanoma that is metastatic or unresectable; if histologic or cytologic confirmation of the primary is not available, confirmation of the primary diagnosis of uveal melanoma by the treating investigator can be clinically obtained, as per standard pr... | NCT_ID
NCT01835145
| Study_NameCabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
| 20,995 |
Study Objectives
This phase III trial is studying combination chemotherapy to see how well it works in treating young patients with newly diagnosed acute promyelocytic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from div... | Inclusion Criteria:
* Patients must be newly diagnosed with a clinical diagnosis of acute promyelocytic leukemia initially by morphology (bone marrow or peripheral blood); bone marrow is highly preferred but in cases where marrow cannot be obtained at diagnosis, peripheral blood will be accepted; APL is considered a h... | NCT_ID
NCT00866918
| Study_NameCombination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
| 7,873 |
Study Objectives
This phase II trial is studying how well erlotinib works in treating patients with locally advanced or metastatic papillary renal cell (kidney) cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth
Conditions: Recurrent Renal Cell Cancer, Stage II... | Inclusion Criteria:
* Patients must have histologically or cytologically confirmed papillary histology renal cell carcinoma which is metastatic (M1); patients with unresectable primary tumor (but M0) are also eligible; patients who have undergone a prior nephrectomy should have histologic confirmation of the metastati... | NCT_ID
NCT00060307
| Study_NameErlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer
| 15,947 |
Study Objectives
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of flavopiridol in treating patients who have relapsed or refractory multiple myeloma
Conditions: Refractory Multiple Myeloma, Stage I Multiple Myelom... | Inclusion Criteria:
* Diagnosis of relapsed or refractory multiple myeloma (MM) requiring treatment
* Durie-Salmon stage I or greater at diagnosis
* Patients with non-secretory or oligo-secretory MM (defined as maximum urinary M-spike less than 200 mg/24 hours and a maximum serum M-spike less than 0.5 g/dL dur... | NCT_ID
NCT00047203
| Study_NameFlavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma
| 17,194 |
Study Objectives
The objective of this study is to evaluate the efficacy and safety of sugammadex in reversing profound neuromuscular block induced by rocuronium in infant patients
Conditions: Brain Cancer
Intervention / Treatment:
DRUG: Sugammadex
Study Design and Phases
Study Type: INTERVENTIONAL
Phase: PHASE4
Pri... | Inclusion Criteria:
* Patients between the ages of 1 <= age <= 12 month,
* ASA physical status 1 <= age <= 3 who underwent elective brain cancer surgery during general anesthesia were included in the study
Exclusion Criteria:
* younger than 1month or older than 12 months.
* hepatic or renal failure
* A history of al... | NCT_ID
NCT02708056
| Study_NameSugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants
| 18,376 |
Study Objectives
This 2 arm study will compare the efficacy and safety of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin in participants who have not received prior chemotherapy for advanced or metastatic gastric cancer. Participants will be rand... | Inclusion Criteria:
* Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable, locally advanced or metastatic disease, not amenable to curative therapy
* Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2
* Measurable disease or non-measurable but eva... | NCT_ID
NCT00887822
| Study_NameA Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer
| 2,906 |
Study Objectives
In the proposed study, investigators will conduct a 90-day dietary intervention study in human subjects. Thirty individuals at risk for adenomatous colon polyp formation will be randomized to receive a calcium and multi-mineral-rich natural product (Aquamin) or a comparable level of calcium alone. Ther... | Inclusion Criteria:
* Must be able to give written informed consent.
* Be generally healthy, male or female, ages 18 <= age <= 80 old.
* Must have one of the following:
i)A first degree relative (father/mother, son/daughter, brother/sister) with colorectal cancer under the age of 60 at the time of diagnosis; OR ii)... | NCT_ID
NCT02647671
| Study_NameAquamin and Prevention of Colon Cancer
| 17,996 |
Study Objectives
This phase II trial studies how well pegylated irinotecan NKTR 102 works in treating patients with small cell lung cancer that has returned after a period of improvement. Pegylated irinotecan NKTR 102 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions... | Inclusion Criteria:
* Written informed consent granted prior to initiation of any study-specific screening procedures, given with the understanding that the patient has the right to withdraw from the study at any time, without prejudice
* Histologic or cytologic diagnosis of SCLC (Note: patients with mixed histology a... | NCT_ID
NCT01876446
| Study_NamePegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
| 13,559 |
Study Objectives
This is an open-label, phase 1 study of ascending multiple oral doses of HKI-272 in combination with paclitaxel.
Conditions: Advanced Malignant Solid Tumors
Intervention / Treatment:
DRUG: Neratinib, DRUG: Paclitaxel
Location: Japan
Study Design and Phases
Study Type: INTERVENTIONAL
Phase: PHASE1
P... | Inclusion Criteria:
* Subjects must have confirmed pathologic diagnosis of a solid tumor that is not curable with available therapy for which HKI-272 plus paclitaxel is a reasonable treatment option.
* At least 1 measurable lesion as defined by RECIST criteria.
* Eastern Cooperative Oncology Group (ECOG) 0 to 1
* LVEF... | NCT_ID
NCT00768469
| Study_NameStudy Evaluating Safety And Tolerability, Solid Tumor
| 11,184 |
Study Objectives
The Influence of ARTISS on post-operative abdominal drainage and seroma formation in DIEP/MS-TRAM free flap breast reconstruction patients.
Conditions: Breast Neoplasms, Mammaplasty
Intervention / Treatment:
DRUG: ARTISS 4mL Fibrin Sealant Topical Solution (Frozen), OTHER: no ARTISS
Location: United... | Inclusion Criteria:
* Female adult (age 18 <= age <= 80)
* Patients planned for immediate or delayed DIEP/MS-TRAM breast reconstruction
Exclusion Criteria:
* Patients who are unable to consent or do not consent
* Clotting disorder
* Pregnancy
* Individuals whose immune system is depressed or who have some types of a... | NCT_ID
NCT04931615
| Study_NameARTISS a Single-centre Randomised Control Study
| 18,819 |
Study Objectives
The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.
Conditions: Pancreatic Cancer
Intervention / Treatment:
DRUG: Gemcitabine, DRUG: LY293111, DRUG: placebo
Location: United States
Study D... | Inclusion Criteria:
* Adenocarcinoma of the pancreas that is locally advanced or metastatic and not amenable to resection with curative intent
* Tumor that can be measured by x-ray or scan
* Adequate organ function
Exclusion Criteria:
* Inability to swallow capsules
* Documented brain metastases
* Prior chemotherapy... | NCT_ID
NCT00055250
| Study_NameA Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer
| 14,442 |
Study Objectives
For cancer patients with inadequate pain relief, a switch to an alternative opioid is the preferred option for symptomatic improvement. However, multiple opioids are often simultaneously administered for anecdotal reasons.
The present study isdesigned to assess the analgesic profiles of two different ... | Inclusion Criteria:
* Chronic Uncontrolled Pain That Required Stronger Opioid Therapy Than They Have Been Taking
* Histologically Confirmed Solid Cancer
* Aged Over 18 Years
* Admitted in a Palliative Cancer Care Unit
Exclusion Criteria:
* Uspected to Have Narcotic Abuse, Clinically Relevant CO2 Retention or Had an ... | NCT_ID
NCT00478101
| Study_NameOpioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain
| 11,316 |
Study Objectives
This Phase IIIb, open-label, multinational, multicenter study will evaluate the participant's satisfaction and safety with subcutaneously administered trastuzumab in participants with HER2-positive early breast cancer. Participants will receive trastuzumab 600 milligrams (mg) administered subcutaneousl... | Inclusion Criteria:
* Eastern Cooperative Oncology Group (ECOG) performance status 0 <= age <= 1
* Hormonal therapy will be allowed as per institutional guidelines
* Prior use of anti-HER2 therapy will be allowed, except for early breast cancer participants in the neo-adjuvant setting
* Left ventricular ejection fract... | NCT_ID
NCT01964391
| Study_NameA Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
| 5,170 |
Study Objectives
This non-interventional retrospective study will describe real-world treatment patterns and clinical outcomes among adults with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations who initiated talazoparib as a first or later line of therapy. Patients will be identified from the Flat... | Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
* Diagnosed with breast cancer (ICD-9 174.x or 175.x or ICD-10 C50x)
* At least two visits in the Flatiron database on or after January 1, 2011
* Pathology consistent with breast cancer
* Has evid... | NCT_ID
NCT05141708
| Study_NameTreatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m
| 17,492 |
Study Objectives
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) plus one of four platinum-based chemotherapy regimens compared to the efficacy and safety of placebo plus one of four platinum-based chemotherapy regimens in the treatment of adult women with persistent, recurrent... | Inclusion Criteria:
* Has persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which has not been treated with systemic chemotherapy and is not amenable to curative treatment (such as with surgery and/or radiation). Prior chemotherapy utilized as a radi... | NCT_ID
NCT03635567
| Study_NameEfficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
| 8,612 |
Study Objectives
This phase II trial studies the side effects and how well white blood cells taken from person's own (autologous) cluster of differentiation (CD)8+ antigen-specific T cells, cyclophosphamide, aldesleukin, and ipilimumab work in treating patients with melanoma that has spread to another place in the body... | Inclusion Criteria:
* ELIGIBILITY FOR ENROLLMENT
* Histopathologic documentation of melanoma concurrent with the diagnosis of metastatic disease
* Expression of human leukocyte antigen (HLA)-A2
* Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status of '0 <= age <= 1' at screening visit
* Women of childb... | NCT_ID
NCT02027935
| Study_NameCD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
| 4,325 |
Study Objectives
The primary objective of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of unesbulin in combination with dacarbazine for the treatment of advanced LMS and determine the overall safety profile of unesbulin in combination with dacarbazine.
This study will... | Inclusion Criteria:
* Signed consent of an Institutional Review Board (IRB)-approved informed consent form (ICF) and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information (if appropriate).
* Willingness and ability to comply with scheduled visits, drug adm... | NCT_ID
NCT03761095
| Study_NameA Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
| 12,893 |
Study Objectives
We plan to conduct a phase I/II clinical trial using biweekly gemcitabine, oxaliplatin, and 48-hour infusion of high dose 5-FU/leucovorin to treat patients with advanced pancreatic adenocarcinoma. In the phase I part, the maximum tolerable dose of oxaliplatin in combination with biweekly gemcitabine 80... | Inclusion Criteria:
* 5.1.1 Patients must have metastatic or unresectable adenocarcinoma of the pancreas. The diagnosis of pancreatic adenocarcinoma must be confirmed by histopathology or cytology.
*1.2 For the phase I part of this trial, patients who have disease measurable or evaluable on x-ray, CAT scan, or physic... | NCT_ID
NCT00154791
| Study_NamePhase I/II Trial GOFL in Advanced Pancreatic Adenocarcinoma
| 6,225 |
Study Objectives
This Prospective, single-arm Phase Ⅱ study is to determine the efficacy and safety of Once-daily Simultaneous Modulated Accelerated Radiotherapy combined with S-1/DDP for geratic esophageal squamous cell carcinoma patients.
Conditions: Esophageal Squamous Cell Carcinoma
Intervention / Treatment:
RADI... | Inclusion Criteria:
* Pathologically or cytologically confirmed esophageal squamous cell carcinoma.
* Stage II-IVa ESCC confirmed by endoscopic ultrasonography(EUS) and imaging studies.
* Aging from 70 to 80.
* Eastern Cooperative Oncology Group (ECOG) performance status 0 <= age <= 2.
* Charlson's weighted index of c... | NCT_ID
NCT02606916
| Study_NameRadiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer.
| 4,685 |
Study Objectives
Primary Objective:
1. To assess the safety and toxicity of imatinib mesylate when given to patients with Ph (+) CML , ALL or AML within the first 100 days following allogeneic bone marrow or stem cell transplantation.
Secondary Objectives:
1. To identify any clinically significant drug interactions ... | Inclusion Criteria:
* Patients with Ph(+) CML and/or CML with bcr-abl rearrangement and diploid cytogenetics not eligible for protocols of higher priority (e.g. ID02 <= age <= 901, DM99 <= age <= 081, DM97 <= age <= 206, etc).
* The disease must be beyond first chronic phase according to IBMTR criteria (i.e. accelerat... | NCT_ID
NCT00386373
| Study_NameUse and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients
| 1,705 |
Study Objectives
The purpose is to identify a dose of SB-485232 which is safe, tolerable and effective when used in combination with Rituximab in patients with non-Hodgkin's lymphoma (NHL). This study will use a standard treatment regimen of Rituximab in combination with rising doses of SB-485232. The dose selected fro... | Inclusion Criteria:
* Histologically confirmed diagnosis of any subtype of CD20+ B cell NHL. Subjects must have disease that progressed after standard therapy or for which there is no effective standard therapy (including high-dose therapy and autologous stem cell transplantation). NOTE: If the subject has had a prior... | NCT_ID
NCT00500058
| Study_NameA Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18
| 2,856 |
Study Objectives
This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate or gemcitabine or romidepsin, in participants with relapsed or refractory peripheral T-cell lymphoma ... | Inclusion Criteria:
* Male or female participants age >= 18 years
* Participants with Peripheral T cell lymphoma (PTCL) (selected subtypes) according to World Health Organization (WHO) criteria and have relapsed or are refractory to at least 1 prior systemic, cytotoxic therapy for PTCL. Participants must have received... | NCT_ID
NCT01482962
| Study_NameAlisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
| 5,598 |
Study Objectives
Regorafenib is a novel oral multi-kinase inhibitor which targets angiogenic, stromal and oncogenic receptor tyrosine kinases. It is currently registered for GIST and mCRC. When regorafenib is co-administered with an acid suppressive agent, the intra-gastric pH increases, and as a result the equilibrium... | Inclusion Criteria:
* Age >= 18 years
* Histological or cytological confirmed diagnosis of mCRC or GIST and prior treatment specific:
1. mCRC-patients who have been previously treated with, or are not considered candidates for, available therapies according to common practice.
2. Irresectable or metastatic GIST... | NCT_ID
NCT02800330
| Study_NameThe Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib
| 476 |
Study Objectives
The purpose of this study is to assess the feasibility of conducting a larger randomized controlled trial to assess the efficacy of perioperative propranolol capsules compared with placebo capsules in decreasing recurrence of prostate cancer (PCa) after robotic assisted laparoscopic prostatectomy (RALP... | Inclusion Criteria:
* European Association of Urology Intermediate- and High Risk for Biochemical recurrence and planned for curative RALP
* ECOG Performance Status 0 <= age <= 1
Exclusion Criteria:
Medical Conditions
* Sick sinus syndrome
* Atrioventricular (AV) block grade 2 and 3
* Recent (3 months) myocardial i... | NCT_ID
NCT05679193
| Study_NamePerioperative Propranolol During Prostatectomy to Decrease Cancer Recurrence
| 19,643 |
Study Objectives
Oral contraceptive therapy is routinely used for the treatment of menstrual disturbances of patients with polycystic ovary syndrome (PCOS).
To date, the cardiovascular risk (CVR) of the oral contraceptives (OC) are known but no data are available on the CVR in PCOS patients treated with OC or physical... | Inclusion Criteria:
* Polycystic ovary syndrome
Exclusion Criteria:
* Age <18 or >40 years
* BMI higher than 30 and lower than 18
* Pregnancy
* Hypothyroidism, hyperprolactinemia, Cushing's syndrome, nonclassical congenital adrenal hyperplasia, use of OC, glucocorticoids, antiandrogens, ovulation induction agents, a... | NCT_ID
NCT00593294
| Study_NameOral Contraceptive and Cardiovascular Risk in PCOS
| 5,128 |
Study Objectives
This clinical trial is assessing compliance with long-term mercaptopurine treatment in young patients with acute lymphoblastic leukemia in remission. Assessing why young patients who have acute lymphoblastic leukemia may not take their medications as prescribed may help identify ways to assist them in ... | Inclusion Criteria:
* Diagnosis of ALL in first remission, irrespective of risk stratification; enrollment on a Children's Oncology Group (COG) therapeutic study for ALL is not required, but the treatment plan must meet the criteria in this protocol
* Belongs to one of the four following ethnic/racial categories: Afri... | NCT_ID
NCT00268528
| Study_NameStudy to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission
| 19,966 |
Study Objectives
This is a randomized, open-label pilot study to assess whether treatment with chlorhexidine mouthwash can alter the esophageal and gastric cardia microbiome
Conditions: Esophageal Adenocarcinoma, Barrett's Esophagus, Reflux Esophagitis
Intervention / Treatment:
DRUG: Chlorhexidine gluconate
Location... | Inclusion Criteria:
* Age >18
* Scheduled for upper endoscopy for clinical indications
* No allergy or other contraindication to chlorhexidine
Exclusion Criteria:
* Use of proton pump inhibitors or H2 receptor antagonists within 1 month of enrollment. Acid suppressant medications raise the gastric pH and can dramati... | NCT_ID
NCT02513784
| Study_NameTrial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome
| 9,003 |
Study Objectives
Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (≥2nd line) (DasaHIT Trial (Dasatinib Holiday for Improved Tolerability))
Conditions: Myeloid Leukemia, ... | Inclusion Criteria:
* Male or female patients with diagnosis of CP-CML with cytogenetic confirmation of Ph+ chromosome [t(9;22)(q34;q11)].
* Ph negative cases or patients with variant translocations who are BCR-ABL positive in multiplex PCR4 will be also considered eligible.
* ECOG performance status <=2.
* Age >= 18 ... | NCT_ID
NCT02890784
| Study_NameDasatinib Holiday for Improved Tolerability
| 8,936 |
Study Objectives
This single center Phase I dose escalation trial will evaluate the safety, tolerability and efficacy of LBH589 when combined with capecitabine and lapatinib in three parts. Part 1 will determine the maximum tolerated doses (MTD) of LBH589 when combined with capecitabine. Parts 2 and 3 will be limited t... | Inclusion Criteria:
* Histologically documented metastatic or locally unresectable, incurable malignancy for which capecitabine is clinically appropriate.
* Male or female patients aged >= 18 years.
* Maximum of 3 prior regimens in a metastatic setting allowed and may include other targeted agents, immunotherapy and c... | NCT_ID
NCT00632489
| Study_NameLBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients
| 5,019 |
Study Objectives
This perspective, mono institutional study is addressed to find potential serum and urine biomarkers predictive of the pharmacokinetic and pharmacodynamic profile of soft tissue sarcomas patients treated with trabectedin.
Conditions: Sarcoma
Intervention / Treatment:
DRUG: Trabectedin
Study Design a... | Inclusion Criteria:
* Advanced Soft Tissues Sarcoma STSs (unresectable and/or metastatic disease).
* One previous systemic treatment with ananthracycline ± ifosfamide.
* Measurable disease, as defined by RECIST criteria.
* ECOG PS <=2.
* Age >=18 years.
* A minimum of 3 weeks since prior tumor directed therapy
* Recov... | NCT_ID
NCT04394728
| Study_NamePharmacometabolomic of Trabectedin in Soft Tissue Patients
| 19,695 |
Study Objectives
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is stud... | Inclusion Criteria
* Participants must be adult males >18 years.
* Patients must have histologically or cytologically confirmed CaP with a Gleason score available or interpretable.
* Patients must have CaP deemed to be androgen independent.
* Measurable disease is not required.
* Patients must have been surgically or ... | NCT_ID
NCT00814788
| Study_NameBicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer
| 20,919 |
Study Objectives
The purpose of this study is to determine the effect of adecatumumab alone or following FOLFOX in patients with R0 resected liver metastases from CRC (colorectal carcinoma) and to compare the effect to FOLFOX alone.
Conditions: Liver Metastases, Colorectal Cancer
Intervention / Treatment:
DRUG: Adeca... | Inclusion Criteria:
* Histopathologically confirmed complete resection (R0) of liver metastases from colorectal adenocarcinoma
* Age >=18 years
* ECOG performance status <= 2
* Patient was informed, has read and understood the patient information / informed consent form and has given written informed consent
Exclusio... | NCT_ID
NCT00866944
| Study_NameStudy of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases
| 3,493 |
Study Objectives
The purpose of this study is to show that Nivolumab will improve progression free survival in subjects with strongly Stage IV or Recurrent PD-L1+ non-small cell lung cancer when compared to chemotherapy
Conditions: Stage IV or Recurrent Non-Small Cell Lung Cancer
Intervention / Treatment:
BIOLOGICAL:... | Inclusion Criteria:
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) <= 1
* Histologically confirmed Stage IV, or Recurrent NSCLC with no prior systemic anticancer therapy
* Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per response evaluation criteria in solid t... | NCT_ID
NCT02041533
| Study_NameAn Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
| 21,059 |
Study Objectives
Skin cancers and pre-cancerous growths (called actinic keratoses, "AKs"), that aren't melanomas, develop in patients with a kidney transplant at excessive rates. When these pre-cancerous AKs, and "non-melanoma" skin cancers occur in kidney transplant patients, they tend to be aggressive, and require fr... | Inclusion Criteria:
* Kidney transplant >= 12-months ago
* ongoing, standard immunosuppression regimen
* current CKD
* EPI estimated (43)
* glomerular filtration rate (eGFR) >= 15 ml/min per 1.73 m2)
* Prior history of at least one NMSC
Exclusion Criteria:
* Kidney transplant <12-months ago, treatment for acute reje... | NCT_ID
NCT04843553
| Study_NameNicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients
| 21,933 |
Study Objectives
The purpose of the study is to learn about the safety and effectiveness of treating follicular lymphoma with bendamustine and rituximab followed by radioimmunotherapy (RIT) using 90-yttrium (Y) ibritumomab tiuxetan.
The researchers will also test blood and bone marrow for the BCL2 gene-Jh that is a co... | Inclusion Criteria:
* Previously untreated, histologically confirmed follicular lymphoma classification grade 1, 2 or 3a
* Ann Arbor stages of II to IV with either symptomatic or bulky disease (>5 cm); or disease progression
* 18 years or older
* ECOG PS <2
* Normal organ and marrow function defined as below:
Absolut... | NCT_ID
NCT01234766
| Study_NameBendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
| 2,777 |
Study Objectives
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have myelofibrosis. Imatinib mesylate may stop the growth of myelofibrosis by blocking certain enzymes necessary for cell growth.
Conditions: Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Polycythemia... | Inclusion Criteria:
* Patients must have histologic confirmation of one of the following diseases-
* Myeloid metaplasia with myelofibrosis (this includes all subtypes- chronic idiopathic myelofibrosis or agnogenic myeloid metaplasia, post thrombocythemic and post polycythemic myelofibrosis) or
* Chronic myelomono... | NCT_ID
NCT00039416
| Study_NameImatinib Mesylate in Treating Patients With Myelofibrosis
| 6,919 |
Study Objectives
This is a Phase 2b randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of elagolix alone and in combination with add-back therapy versus placebo on heavy menstrual bleeding in premenopausal women 18 to 51 years of age with uterine fibroids.
Conditions: Heavy Uterine B... | Inclusion Criteria:
* Subject is pre-menopausal female 18 <= age <= 51 of age at Screening.
* Subject has diagnosis of uterine fibroids documented by a Pelvic Ultrasound.
* Subject has heavy uterine bleeding associated with uterine fibroids.
Exclusion Criteria:
* Subject has had a myomectomy, uterine artery emboliza... | NCT_ID
NCT01817530
| Study_NameSafety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
| 553 |
Study Objectives
This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one of these drugs, and followed for efficacy and tolerance of each.
Condition... | Inclusion Criteria:
* advanced measurable Non-Small Cell Lung Cancer (NSCLC);
* progressed after 1 <= age <= 2 prior chemotherapy;
* Eastern Cooperative Oncology Group (ECOG) 0 <= age <= 2;
* tissue available for future KRAS/ EGFR testing
Exclusion Criteria:
* prior Epidermal Growth Factor Receptor (EGFR) targeted t... | NCT_ID
NCT00769067
| Study_NameA Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
| 9,639 |
Study Objectives
The purpose of this study is to learn the effects (both good and bad) that celecoxib has on prostate cancer and patients with prostate cancer. This study is looking at what effects celecoxib has on prostate specific antigen (PSA) level. PSA is a marker specific to prostate cancer. An increase or decrea... | Inclusion Criteria:
* Diagnosis of prostate cancer
* Progression following prostatectomy or radiation to the prostate, defined as 3 PSA rises, with each PSA determination at least 4 weeks apart
* PSA greater than or equal to 1.0 for men who had a prostatectomy
* PSA greater than or equal to 3.0 for men who were treate... | NCT_ID
NCT00136487
| Study_NameCelecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer
| 17,551 |
Study Objectives
Investigation of absorption, distribution, metabolism and excretion (ADME) and assessment of safety, tolerability and preliminary therapeutic effects of \[14C\]volasertib in patients with advanced solid tumours.
Conditions: Neoplasms
Intervention / Treatment:
DRUG: BI 6727
Location: Hungary
Study D... | Inclusion criteria:
* Inclusion Criteria 1. Patients with histologically or cytologically confirmed diagnosis of advanced, non resectable and / or metastatic solid tumour
* Inclusion Criteria 2. Male
* Inclusion Criteria 3. Age >=18 and =<70 years
* Inclusion Criteria 4. Written informed consent
* Inclusion Criteria 5... | NCT_ID
NCT01145885
| Study_NameBI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours
| 19,392 |
Study Objectives
In this study it will be determined whether the rate of severe toxicity associated with fluoropyrimidine treatment (capecitabine or 5-fluorouracil) can be significantly diminished by individualized dosing of fluoropyrimidines based on upfront genotypic assessment of dihydropyrimidine dehydrogenase (DPD... | Inclusion Criteria:
* Pathologically confirmed malignancy for which treatment with a fluoropyrimidine is considered to be in the patient's best interest
* Age >= 18 years
* Able and willing to give written informed consent
* WHO performance status of 0, 1 or 2
* Life expectancy of at least 12 weeks
* Able to swallow a... | NCT_ID
NCT02324452
| Study_NameSafety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines
| 15,863 |
Study Objectives
The purpose of this study is to determine the effect of exemestane on the pharmacokinetics (PK) of entinostat and to determine the effect of entinostat on the PK of exemestane in patients with locally recurrent or metastatic estrogen receptor positive (ER+) breast cancer. Additionally, this study will ... | Inclusion Criteria:
* Postmenopausal female patients
* Histologically or cytologically confirmed ER+ breast cancer at initial diagnosis and have locally recurrent or metastatic disease that has progressed to where the patient is a candidate to receive exemestane as determined by the Investigator
* Patients receiving p... | NCT_ID
NCT02820961
| Study_NameDrug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
| 18,642 |
Study Objectives
The purpose of this study is to find out if complementary and alternative medicines (CAM) should be included with traditional therapy for women with ovarian cancer. Some of the alternative medicines include non-traditional drug and herbal therapies along with dietary and nutritional strategies. Only a ... | Inclusion Criteria:
* A diagnosis of ovarian cancer
* An Eastern Cooperative Oncology Group (ECOG) score of 2 or less with a life expectancy of at least 12 months
* A patient being treated by a gynecologic oncologist in the Center for Women's Oncology
* Ability to read, understand, and sign the informed consent form
*... | NCT_ID
NCT01419210
| Study_NamePilot Program to Personalize Care & Improve Quality of Life for Women With Ovarian Cancer
| 13,063 |
Study Objectives
Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) the male hormone that leads to benign prostate growth. By blocking the conversion of testosterone to DHT, dutasteride could allow bicalutamide to be a more effective anti-androgen thus prolonging bicalutamide's efficacy.
... | Inclusion criteria:
* Men >=40 and <=90 years
* Must have asymptomatic prostate cancer that has progressed during androgen deprivation therapy (rising PSA). PSA progression must have occurred after first-line treatment with GnRH analogues ( e.g. leuprolide, goserelin) or orchiectomy. PSA progression is defined by thre... | NCT_ID
NCT00470834
| Study_NameProstate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
| 7,445 |
Study Objectives
Primary:
* To assess complete pathological response rate of both strategies.
Secondary:
* Safety profile
* To assess downstaging rate of both strategies.
* To compare relative dose intensity of oxaliplatin and capecitabine of both strategies
* To compare time to progression and overall survival of b... | Inclusion Criteria:
* Patients with rectal adenocarcinoma.
* Operable tumour, confirmed by magnetic resonance of high resolution and / or endorectal echography, or,
* Rectal tumour at distal third, or
* Tumours spread more than 5 mm in perirectal fat
* Functional state ECOG <= 2.
* Good hematological, hepatic and rena... | NCT_ID
NCT00421824
| Study_NameStudy of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer
| 8,091 |
Study Objectives
This is an open-label, international, multi-center study designed to provide access to pazopanib for subjects who have been enrolled in the Phase III renal cell carcinoma study (VEG105192) and have progressed on placebo. Subjects will receive 800 mg pazopanib once daily. The study treatment will contin... | Inclusion criteria:
* Progressed from VEG105192 study treatment
* Patient's VEG105192 was placebo
* Baseline has good organ function
Exclusion criteria:
* No brain metastasis | NCT_ID
NCT00387764
| Study_NameExtension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
| 16,119 |
Study Objectives
We conducted a randomized controlled trial of adjuvant interferon (IFN) therapy in patients with hepatitis-C virus (HCV)-related cirrhosis who underwent curative resection of hepatocellular carcinoma (HCC) to investigate whether IFN could reduce or delay the incidence of recurrent tumor (secondary/tert... | Inclusion Criteria:
* HCV-RNA positive / HBsAg-negative patients with HCC undergoing potentially curative resection
* Curative surgery (i.e. no residual tumor intraoperative US and tumor-free margins at pathology)
* No recurrence 1 month after surgery (CT, NMR, US)
* Pre-resection treatments allowed (TACE, RFA, PEI)
*... | NCT_ID
NCT00273247
| Study_NameTreatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis
| 21,537 |
Study Objectives
This phase II trial compares how well gallium 68-labeled PSMA-11 positron emission tomography/computed tomography (PET/CT) works compared to fluciclovine F18 PET/CT in imaging participants with prostate cancer after surgery that has come back. PET is an established imaging technique that uses small amo... | Inclusion Criteria:
* Histopathologically proven prostate cancer (PCa)
* Radical prostatectomy as definitive treatment for PCa
* Proven biochemical recurrence as defined by American Urological Association (AUA) recommendation: PSA greater than or equal to 0.2 ng/mL measured more than 6 weeks after radical prostatectom... | NCT_ID
NCT03515577
| Study_NameGallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery
| 21,563 |
Study Objectives
In this study, the investigators designed a treatment regimen including the most active agents in pancreatic cancer which are gemcitabine and fluorouracil to be tested as a first line treatment. This regimen is expected to be less toxic than FOLFIRINOX and aiming at better outcomes.
Conditions: Cancer... | Inclusion Criteria:
* Histopathological evidence of adenocarcinoma of the pancreas
* Radiological proof of metastatic disease as defined by AJCC
Exclusion Criteria:
* patients with poor performance status (ECOG 4)
* patients with organ dysfunction defined as: creatinine more than 1.6 mg/dl or bilirubin more than 3 m... | NCT_ID
NCT04769414
| Study_NameFlouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)
| 8,781 |
Study Objectives
This study aimed to provide vast clinical information to facilitate breast sonographic examination for participants who underwent recent SARS-CoV-2 vaccination.
Among different SARS-CoV-2 vaccines in the Asian Taiwanese population, reactive axillary lymphadenopathy was investigated through breast sono... | Inclusion Criteria:
* female patients receiving breast sonography
Exclusion Criteria:
* receive Covid 19 vaccine other than AZ, BNT, Moderna
* Ongoing primary breast malignancy
* History of malignancy other than primary breast malignancy | NCT_ID
NCT06429020
| Study_NameSonography for COVID-19 Vaccines Related Reactive Lymphadenopathy
| 3,156 |
Study Objectives
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with paclitaxel and bevacizumab and to see how well they work in treating patients with metastatic breast cancer and/or breast cancer that has recurred in the chest wall and cannot be removed by surgery. ... | Inclusion Criteria:
* histologically or cytologically confirmed adenocarcinoma of the breast; effective with version 2.2 (1/26/09), only patients with disease that is accessible to biopsy and consent to serial biopsy are eligible
* stage IV disease, locally recurrent inoperable chest wall disease; at least one bidimen... | NCT_ID
NCT00368875
| Study_NamePhase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer
| 12,534 |
Study Objectives
CC-5013-MM-017 is a Phase I, multicenter study to determine the maximum tolerated dose (MTD), safety profile, pharmacokinetics, and preliminary efficacy of lenalidomide with and without dexamethasone in Japanese subjects with previously treated MM. The study will consist of two cohorts: 1) Monotherapy ... | Inclusion Criteria:
* Subjects with previously treated multiple myeloma
* Measurable levels of m-protein in serum >= 0.5 g/dL [5g/L]) or urine (>= 0.2 g excreted in a 24-hour collection sample)
* ECOG performance status of 0 - 2
* Willing to follow pregnancy precautions
Exclusion Criteria:
* Patients with acute an m... | NCT_ID
NCT00555100
| Study_NameSafety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma
| 11,419 |
Study Objectives
Patients with acute lymphoblastic leukaemia or very aggressive lymphoma and documented isolated CNS relapse or CNS relapse combined with other relapse sites should receive therapy with intrathecal DepoCyte at least once. Treatment may be repeated during induction phase each 2 weeks and monthly during m... | Inclusion Criteria:
* proven diagnosis of ALL or very aggressive Non-Hodgkin-Lymphoma (Burkitt/Burkitt-like) and CNS relapse
* CNS involvement demonstrated by a positive ventricular or lumbar CSF cytology or characteristic signs and symptoms of neoplastic meningitis plus an MRI or CT scan indicating the presence of me... | NCT_ID
NCT00199108
| Study_NameTreatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt
| 12,770 |
Study Objectives
Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced chondrosarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2. This s... | Inclusion Criteria:
* 1) histologically confirmed high-grade sarcoma;
* 2) initial treatment in the orthopedic oncology departments of the two affiliated hospitals of Peking University;
* 3) tumors not amenable to curative treatment or inclusion in clinical trials;
* 4) unresectable local advanced lesions or multiple ... | NCT_ID
NCT04260113
| Study_NameApatinib for Inoperable Advanced Chondrosarcoma
| 7,552 |
Study Objectives
This study is done in patients having Breast Cancer with metastasis (patients with positive receptor HER2) whose disease progressed after receiving Trastuzumab.
The primary objective of this study is to compare the time until disease progression between the Treatment Arm CAPECITABINE and the Treatment... | Inclusion Criteria:
* Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements.
* Pathologically confirmed carcinoma of the breast.
* Locally a... | NCT_ID
NCT00148876
| Study_NameTBP Study With Capecitabine Plus Minus Trastuzumab
| 3,242 |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 5